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Abstract
Proficiency testing (PT) is a valuable tool for assessing laboratory performance and verifying the 
accuracy and reliability of test results. Participation is required by the Clinical Laboratory 
Improvement Amendments (CLIA) of 1988 for each of the microbiology subspecialties 
(bacteriology, mycobacteriology, mycology, parasitology, and virology), and the regulations 
include specific PT requirements for each subspecialty. To determine the use and perceived value 
of PT beyond meeting CLIA requirements, the Centers for Disease Control and Prevention funded 
a cooperative agreement with the Association of Public Health Laboratories to convene a series of 
focus groups to query laboratory professionals responsible for PT. The seven focus groups were 
comprised of 60 laboratory professionals representing large and small clinical laboratories, 
microbiology subspecialties, and public health. While participants acknowledged the need to 
perform PT to meet regulatory requirements, many also cited benefits and challenges beyond 
regulatory compliance.
Introduction
Clinical microbiology laboratory testing plays an important role in the detection, diagnosis, 
and treatment of infectious diseases and public health disease surveillance. Microbiology 
laboratories are often the first lines of defense in the detection of antibiotic resistance and in 
the identification of outbreaks of, e.g., food-borne infection, and are responsible for 
reporting certain infectious diseases to public health authorities. Therefore, it is critical to 
ensure high-quality testing and results that are accurate and precise. The Clinical Laboratory 
Improvement Amendments (CLIA) of 1988 (Public Law 100–578) created uniform quality 
standards for all laboratory testing to ensure the accuracy, reliability, and timeliness of 
patient test results regardless of where the testing is performed (1). The regulations that 
implemented the law were published in the Federal Register on 28 February 1992 (2) and 
were updated in the Federal Register on 24 January 2003 (3). These requirements for 
laboratories and other testing sites are based on the technical complexity of the testing 
performed within three test categories specified in the regulations: waived, moderate 
complexity, and high complexity. All laboratories must have the appropriate CLIA 
certificate issued by the Centers for Medicare & Medicaid Services (CMS) for the testing 
they perform. Microbiology laboratories that conduct moderate- or high-complexity (non-
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waived) testing, which includes most microbiology laboratories, need to meet the standards 
in the regulations for these testing categories and must have a CLIA Certificate of 
Compliance (CoC) or a CLIA Certificate of Accreditation (CoA). CoCs are issued to 
laboratories by CMS through individual state agencies, whereas CoA laboratories are 
voluntarily accredited by a CMS-approved professional organization. A list of approved 
accrediting organizations under CLIA can be found at http://www.cms.gov/Regulations-and-
Guidance/Legislation/CLIA/Downloads/AOList.pdf. Accredited laboratories meet the 
accrediting agency’s requirements as a mechanism for satisfying the requirements for CLIA 
certification. Although these requirements may not be identical to those in the CLIA 
regulations, overall, they are equal to or more stringent than CLIA at the condition level. 
Table 1 shows the number of CLIA certificates issued to each of the microbiology 
subspecialties, as of December 2012, identified in the Online Survey, Certification and 
Reporting (OSCAR) database maintained by CMS. It includes microbiology laboratories 
inspected by CMS, those that are accredited, and microbiology laboratories in the CLIA-
exempt states of New York and Washington.
CLIA PT Requirements for Microbiology
Proficiency testing (PT) is a means of external quality assessment that is one of the main 
facets of the CLIA quality system for non-waived testing. It is a valuable tool for assessing 
laboratory performance and verifying the accuracy and reliability of test results. CLIA 
mandates that all laboratories that perform certain non-waived testing participate in a PT 
program approved by CMS. For clinical microbiology PT, laboratories are sent multiple 
simulated clinical specimens for analysis using the laboratory’s established methods for 
testing patient specimens. The test results are submitted to the PT program for analysis, and 
the laboratory’s individual performance is graded using specified CLIA scoring criteria with 
either a peer group or an assigned target determined by selected referee laboratories. PT 
permits a laboratory to assess its performance and provides confidence that the laboratory’s 
performance conforms to quality expectations required for patient care. Studies have shown 
the value of an external quality assessment program, such as PT, as an indicator for 
maintaining and improving the quality of laboratory results (4–7).
Microbiology laboratories conducting non-waived testing need to meet general PT 
requirements, which include the following:
• Enroll in a CMS-approved PT program for each specialty and subspecialty for 
which testing is performed. A list of CMS-approved PT programs can be found 
online at http://www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/
Downloads/ptlist.pdf.
• Analyze at least five PT samples per testing event.
• Obtain an 80% correct score on each testing event to achieve satisfactory 
performance.
• Perform satisfactorily on two out of three testing events for successful 
performance.
• Test PT samples in the same manner as testing is performed for patient specimens.
Stang and Anderson Page 2
. Author manuscript; available in PMC 2015 December 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
• Perform PT for the primary method, test system, or examination used for patient 
testing.
• Do not send PT samples or portions of samples to another laboratory for analysis.
• Do not engage in inter-laboratory communication pertaining to PT until after the 
due date for reporting results to the PT program.
Since microbiology does not have analytes as indicated in other specialties, CLIA requires 
PT for each subspecialty of microbiology: bacteriology, mycobacteriology, mycology, 
parasitology, and virology. Table 2 lists the CLIA PT requirements for the microbiology 
subspecialties.
For tests not specified in the PT regulations, such as fungal antigen detection, antifungal 
susceptibility testing, and parasite antigen detection, CLIA requires laboratories to ensure 
accuracy at least twice annually for all tests performed. One way this can be accomplished is 
by enrolling in a voluntary PT program for the test. Modules that generally have fewer 
samples or fewer shipments per year that require PT are offered by many PT programs. Test 
results for these modules are scored by the programs and returned to participants, who can 
compare scores to verify the accuracy of the testing. Another way in which laboratories can 
check the accuracy of testing when PT is not required is to split patient specimens with 
another laboratory that offers the same test. The laboratory director can review and compare 
results for acceptability. Laboratories can also perform in-house blind testing of samples 
with known organisms or use photographic images from a reference source to verify the 
identification accuracy of tests when PT is not required or available. CMS provides a 
brochure (CLIA Proficiency Testing Do’s and Don’ts) that is available at http://
www.cms.gov/Regulations-and-Guidance/Legislation/CLIA/Downloads/
CLIAbrochure8.pdf.
Steps of the PT Process
Enrollment
The first step in the PT process should begin with a review of the PT requirements for each 
subspecialty of microbiology shown in Table 2. Once the tests performed by the laboratory 
are determined, the laboratory needs to enroll in a CMS-approved PT program that offers 
modules for those tests. Laboratories may need to enroll in more than one PT program to fit 
their service needs. Some PT programs provide individual modules for specific culture 
types, such as urine or throat cultures. These types of modules are useful for small 
laboratories, such as physician office laboratories (POLs) that only perform cultures on 
limited specimen types. The programs will assist laboratories with selecting the appropriate 
enrollment options, if needed. Once enrolled, PT programs will submit laboratory 
enrollment information to the CMS PT database. On occasion, laboratories may wish to 
change PT programs due to factors such as module cost, module configuration, or number of 
peer participants. They may not randomly change from one program to another but must 
enroll and participate in a PT program for 1 year before changing to a new program. For 
laboratories operating under a new CLIA certificate or adding a new test or specialty, 
enrollment in PT should occur as soon as possible.
Stang and Anderson Page 3
. Author manuscript; available in PMC 2015 December 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Sample Processing and Testing
Some PT programs will provide information on the sample source and clinical history. For 
many laboratories, this information is essential because it will dictate which media to use 
and/or which test to perform when microbial identification is required. For some PT, sample 
preparation may be necessary before testing, as PT programs use different types of samples 
depending on the test to be performed, and they are often shipped as a powder or concentrate 
that requires reconstitution or dilution. Lyophilized microorganisms may have different 
behavioral properties than their live counterparts, and errors in sample preparation can lead 
to inaccurate test results. In many cases, culture of organisms is not required to perform 
antigen-screening tests, so programs may send out non-viable organisms for antigen-testing 
PT. In addition, because it is sometimes not cost-effective for PT programs to provide 
samples that can be used for multiple tests, such as culture, antigen detection, PCRs, or other 
molecular tests, as would occur with patient testing, PT samples that can be used only for a 
particular method of testing are often provided.
After preparation, PT samples should be tested in the same manner as patient specimens to 
the extent possible, even if the samples do not look like actual microbiology specimens and 
require processing that would not be done for patient specimens. Laboratories should avoid 
repeat testing of PT samples when patient specimens are only tested once, and PT should be 
rotated among all the testing personnel who are involved in patient testing.
Results Reporting
When testing PT samples, laboratories are instructed to perform all testing and report results 
as they normally would on a patient specimen; laboratories should report PT results for 
organism identification to the same level that they would for patient testing, e.g., 
“Escherichia coli” versus “Gram-negative organism present.” As a result, microbiology PT 
can be challenging and confusing with respect to the reporting of different identification 
levels. For instance, one laboratory may report growth/no growth if that is their practice for 
reporting patient results, whereas another laboratory may report the same challenge 
organism to the genus or species level, resulting in numerous possible correct answers. 
Under other circumstances, laboratories may vary the level of organism identification based 
on the culture source, such as reporting only to the genus level on urine cultures. PT 
programs provide an attestation statement that must be signed by the analyst and the 
laboratory director or designee certifying that PT samples were tested in the same manner as 
patient specimens, including reporting the microorganism identification to the same level 
and in the same way that results are reported for patient specimens.
After testing, PT result forms or on-line result submissions should be carefully reviewed to 
avoid common clerical or calculation errors. All results should be submitted by the date 
specified by the PT program. Records documenting the handling, preparation, processing, 
and examination and each step in the testing and reporting of PT results must be maintained 
for a minimum of 2 years from the date of each PT event. Regulatory inspectors may request 
PT records and raw data used to generate results, and the information must be accessible and 
retrievable within a reasonable time during a laboratory inspection.
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Scoring and Evaluation of Results
After PT programs have analyzed all the results for an event, they will send each laboratory 
their scores, including a summary or evaluation for each test in the PT event. The 
evaluations provide details on the performance of each test system used by the PT program’s 
participating laboratories. When each laboratory receives its results, the laboratory should 
compare them with the inter-laboratory comparisons provided in the summaries or 
evaluations by the PT programs. When a laboratory submits incorrect PT results or does not 
receive a passing score on a graded event, it should review the results submitted to identify 
the cause of any errors, including clerical or transcription mistakes. In cases of 
unsatisfactory performance or PT problems, the laboratory needs to document the 
investigation, corrective action, and ongoing monitoring.
In microbiology, unsuccessful PT performance means failure to attain a satisfactory score 
for a subspecialty or specialty for two consecutive or two of three consecutive testing events. 
If this occurs in a CoA laboratory, the appropriate accreditation organization would instruct 
the facility to undertake training or obtain technical assistance. For a CoC laboratory with 
initial unsuccessful PT, the CMS regional office may allow the state agency to request that 
the laboratory undertake training and obtain technical assistance, provided the laboratory has 
a good history of compliance with CLIA and there is no immediate jeopardy to patient 
testing, no history of PT referral, and no current significant quality problems. The laboratory 
must have also agreed to correct the problem causing the unsuccessful PT. Repeated, 
unsuccessful PT performance for the same subspecialty or specialty may result in the 
laboratory no longer being allowed to perform the failed testing in the affected subspecialty. 
After a laboratory has identified the reason(s) for the unsuccessful performance and 
corrective action has been taken and documented, the laboratory must perform two 
consecutive PT events successfully for re-instatement. As with other PT documents, if any 
corrective actions are taken as a result of an unsatisfactory or unsuccessful PT score, the 
records should be maintained for 2 years.
CLIA PT Referral
Sending all or part of a PT sample to another laboratory for testing or communication with 
another laboratory about PT results is considered PT referral even if patient specimens are 
routinely sent out for additional or confirmatory testing. PT result report forms may contain 
the option to select “test not performed” or “would refer” in cases where actual patient 
specimens would be sent to another laboratory for confirmation or identification testing. If a 
laboratory receives PT samples from another laboratory for testing, they should notify the 
appropriate inspecting agency (regional office, state agency, or accreditation organization) 
and should not perform testing on the samples. Over time, CMS has investigated numerous 
PT referral cases. If a finding of PT referral is confirmed, serious sanctions are taken by 
CMS against the laboratory, laboratory director, and laboratory owner. The possible 
penalties include loss of the laboratory’s CLIA certificate for at least 1 year, prohibition of 
the director from directing a laboratory for 2 years, and prohibition of the laboratory owner 
from owning or operating a laboratory for 2 years.
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An amendment to the CLIA law, the Taking Essential Steps for Testing (TEST) Act of 
2012, H.R. 6118 (8), signed by the president in December 2012, is intended to resolve the 
longstanding issue of CLIA enforcement due to unintentional PT referral. The TEST Act 
clarifies that sending a PT sample to another laboratory for analysis is prohibited, despite the 
requirement that PT samples be treated like other patient specimens. The act gives the 
Secretary of Health and Human Services discretion as to whether to revoke a laboratory’s 
CLIA certificate for 1 year in the event of a PT referral violation and additional discretion to 
substitute intermediate sanctions in lieu of a mandatory 2-year ban on a laboratory director 
and laboratory owner if the CLIA certificate is revoked. Under this change, CLIA certificate 
revocation for a laboratory may become optional rather than mandatory. Rulemaking to 
define when the discretion will be applied and when revocation will be imposed is 
forthcoming from CMS. In the meantime, the TEST Act does not change the requirement 
that laboratories be prohibited from sending PT samples or portions of PT samples to 
another laboratory and that any laboratory receiving a PT sample from another laboratory 
must report the receipt to CMS.
Use and Value of PT Beyond Meeting Regulatory Requirements
In addition to using PT as a way to meet regulatory requirements, microbiology laboratories 
can realize other benefits. To obtain the perspective of laboratory professionals on the value 
of PT, the Association of Public Health Laboratories (APHL) conducted an informal survey 
of approximately 30 attendees at the Clinical Laboratory Management Association (CLMA) 
May 2010 ThinkLab meeting. Survey questions addressed the use of PT beyond meeting 
regulatory requirements for the purpose of improving the quality of testing, the benefits and 
challenges of PT, and satisfaction with services offered by PT programs. The CLMA survey 
results prompted a CDC-funded cooperative agreement with APHL to obtain additional 
information on the challenges and benefits of PT beyond its use in meeting regulatory 
requirements (9).
Focus Group Participant Selection
As stated above, CDC funded a cooperative agreement with APHL to convene a series of 
focus groups to query laboratory professionals responsible for PT in their facilities as to 
their use of PT and its perceived value. To our knowledge, this laboratory perspective had 
not previously been explored; the focus group format allowed the topic to be investigated 
through questions developed around the use of PT. The individuals selected for the focus 
groups were primarily laboratory professionals with supervisory or managerial status and 
decision-making responsibilities related to PT. A total of 60 participants were recruited from 
hospitals, independent public health laboratories, and POLs located within an approximately 
50-mile radius or less than one driving hour from one of the focus group sites (Atlanta, GA; 
Houston, TX; Boston, MA; and New Orleans, LA). Participants from four facility categories 
were targeted for inclusion in the focus group sessions: large multi-specialty laboratories, 
small multi-specialty laboratories, public health laboratories, and microbiology laboratories. 
All categories included facilities that performed microbiology testing as part of their test 
menu, but the specific microbiology laboratory category consisted of laboratory directors or 
personnel who worked specifically in microbiology. One microbiology focus group 
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consisting of six participants was held in Houston, TX, and another group consisting of 12 
participants coincided with the 111th General Meeting of the American Society for 
Microbiology in New Orleans, LA. Eleven public health laboratories were identified through 
the APHL database and recruited from the northeast region for a focus group in Boston, 
MA. This group consisted of both local and state public health laboratories that do not 
function as part of a university hospital system and included a food/agricultural laboratory in 
Florida.
For the purpose of the focus groups, large laboratories were defined as those having a yearly 
test volume greater than the median OSCAR database volume of 300,000 tests. Small 
laboratories were defined as those having a yearly test volume less than the median OSCAR 
database volume of 300,000 tests per year. Regardless of their test volumes, microbiology 
laboratories were identified through OSCAR as those laboratories that conduct bacterial 
culture identification.
Table 3 shows the participant demographics of the focus groups’ four facility categories. 
There were 13 participants representing small laboratories, 18 participants representing large 
laboratories, 18 participants representing microbiology laboratories (both large and small), 
and 11 participants representing public health laboratories, some of which performed 
microbiology testing. Of the 60 facilities, 9 (15%) self-identified as CMS CoC laboratories; 
the remaining 51 (85%) reported being accredited by CMS-approved accrediting 
organizations. Five (46%) of the 11 public health laboratories identified themselves as CoC 
laboratories. Five (39%) of the 13 small laboratories were classified as POLs; of those five 
POLs, 4 self-identified as CoC laboratories. Attempts were made to recruit both large and 
small laboratories to include both CoA and CoC laboratories. However, smaller laboratories 
tended to be more difficult to recruit due to limited staff availability.
Focus Group Findings
In all focus groups conducted, participants shared information concerning the relationship of 
PT to overall quality assurance, including the analytical process, personnel competency, and 
satisfaction with PT program services. Table 4 summarizes the responses provided by the 
focus groups regarding the primary benefits of performing PT beyond meeting regulatory 
requirements. In these responses, participants stated that the most important benefits of PT 
included the following:
• Provides value as a quality indicator
• Instills confidence in the quality of a laboratory’s performance
• Provides educational opportunities
• Serves as a tool for evaluation of staff competency
• Allows peer group comparisons of test results
In addition to the benefits of PT, participants identified many challenges with the CLIA 
requirement to treat PT samples the same as patient specimens. Concealing the identity of 
PT samples is difficult, since the samples often do resemble actual patient specimens, and 
PT samples may require more instruction on handling, testing, and reporting results than 
Stang and Anderson Page 7
. Author manuscript; available in PMC 2015 December 30.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
would be required for patient tests. Table 5 summarizes the challenges focus group 
participants identified as significant with respect to PT. For microbiology, most agreed that 
the quality of photo-micrographic images is poor in bacteriology and parasitology, 
particularly for Gram stains. Image quality and size may be distorted, although it was their 
opinion that images do not adequately measure testing proficiency. Many of the 
microbiology respondents observed that while Gram stains of patient specimens would be 
examined by microscopically viewing multiple fields before reporting results, Gram stain 
PT often relies on observation of one photo-micrographic image. Most questioned the value 
of identifying any organism by one photomicrograph or one slide field with no other 
pertinent information, which is not consistent with how they would approach Gram stain 
examination in the laboratory.
While there were many instances in which the perception and the use of PT were similar for 
all groups, issues from large facilities, microbiology laboratories, and public health 
laboratories mainly focused on overall PT program requirements and services. In these 
laboratory types, the PT process was facilitated due to increased numbers of staff, and PT 
was viewed as an educational opportunity rather than just a regulatory requirement. Larger 
laboratories, however, expressed concern over the slow response of PT programs to make 
PT available for new technologies. The smaller facilities tended to focus on meeting the 
CLIA PT requirements while fitting the PT samples into their routine without jeopardizing 
patient testing. Meeting the requirements of PT testing was seen as an additional strain at 
these sites. Smaller facilities noted the value of PT in competency assessment and education 
but did not utilize it as an educational tool to the same extent as the larger facilities. 
Regardless of facility size, the majority of participants stated that the most important benefit 
of PT is its value as a quality indicator, and as such, they acknowledged that PT increases 
confidence in the quality of a laboratory’s performance.
Although participants valued PT as an integral part of a laboratory quality control program, 
throughout the focus group discussions, recommendations were made for improvement. 
Table 6 summarizes these recommendations for PT improvement in relation to PT cost, PT 
sample/module configurations, and PT reporting. To cut back on costs, participants 
suggested the ability to purchase customized modules that would allow laboratories to 
choose PT tests as a customizable group.
In addition to the general questions, the microbiology laboratory and public health 
laboratory focus group participants were asked several questions on microbiology-specific 
topics, including PT background/patient information provided with the samples, PT 
microorganism identification reporting-level consistency, PT for individual microbiology 
tests rather than combined scores for each subspecialty, and the possible impact of 
increasing the number of microbiology PT challenges beyond what is now required by 
CLIA. Most participants felt that the background information provided with the PT samples 
was comparable to the information provided with patient specimens. Several participants 
stated they would prefer to have more information but cited only name and sex as needed to 
enter the samples into their system. To ensure that the reporting of PT results for organism 
identification is consistent with the level of reporting for their laboratories, most participants 
reported that the PT instructions require that PT results be reported to the same level as for 
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patient specimens. Since the workflow mirrors patient testing processes and procedures, PT 
samples are reported at the same level as patient specimens. Currently, a combined 
subspecialty score is provided by PT programs to laboratories for microbiology. Participants 
agreed that having an individual score for each testing procedure in addition to the combined 
score could identify areas in need of targeted training for performance improvement. Several 
microbiology laboratory participants supported having more PT susceptibility testing 
challenges to ensure confidence in patient results. An additional benefit of PT noted by 
many microbiology focus group participants is the use of PT samples as an important source 
for stock cultures of organisms that are not commonly identified in their facility. After the 
PT has been completed, the organisms are then available for use in training and competency 
assessments. Lastly, most participants would welcome the challenge of organisms that are 
more difficult to identify or less frequently seen and fewer negative samples in microbiology 
PT.
Conclusion
Based on the findings from these focus groups conducted by APHL, it appears that many 
laboratories use their PT results internally for quality improvement, in addition to fulfilling a 
regulatory requirement. Many non-regulatory benefits were expressed in common across 
focus groups, including the use of PT to ensure confidence in the quality of a laboratory’s 
performance, its use and value in demonstrating staff competencies, and education and 
training of testing personnel. However, participants also mentioned the challenges of PT, 
including the CLIA requirement to treat PT samples the same as patient specimens; 
administrative issues, such as staff time and PT program costs; and PT sample quality, 
including poor photographic images. In conclusion, since laboratories already pay for PT 
materials, the use of PT for quality improvement purposes has the potential to further 
improve laboratory quality at no additional cost to U.S. clinical laboratories.
Looking Ahead
Since the CLIA PT regulations have not been revised since they were implemented in 1994, 
CMS and CDC are now developing a proposed rule to update the PT requirements for all 
laboratory specialties. In September 2010, the Clinical Laboratory Improvement Advisory 
Committee (CLIAC), charged with providing scientific and technical advice on issues 
pertaining to CLIA and laboratory quality to the Department of Health and Human Services, 
including the three government agencies (CDC, CMS, and FDA) with shared responsibility 
for the CLIA program (10), made 23 recommendations addressing possible changes to the 
CLIA requirements for PT, which can be found at http://wwwn.cdc.gov/cliacpdf/
CLIAC0910.pdf. The recommendations covered all laboratory specialties, including changes 
to microbiology PT. Levels of service, required categories of tests, major groups of 
microorganisms included in PT, Gram stain PT, mixed-culture requirements, antimicrobial 
susceptibility testing, direct antigen testing, and monitoring microbiology performance over 
time were all addressed in the CLIAC recommendations and are being considered as the 
proposed regulatory changes are developed.
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The focus group findings prompted APHL and CDC to develop an anonymous online survey 
that will be disseminated later this year (2013) to all laboratories that are required to perform 
PT under CLIA. The target laboratories include 20,500 CoC laboratories and 16,800 CoA 
laboratories. The primary goals are to better understand the perceived benefits and burdens 
of performing PT and to conduct a systematic analysis in order to understand laboratory PT 
practices, to identify ways that practices could be better promoted, and to identify 
laboratories that would benefit from receiving additional information.
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Table 1
Total number of CLIA certificates issued for the microbiology subspecialtiesa
Subspecialty No. of certificatesb
Bacteriology 26,739
Mycobacteriology 2,909
Mycology 20,930
Parasitology 19,973
Virology 9,346
a
Data obtained from CMS OSCAR database (17 December 2012).
b
Including laboratories in exempt states.
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Table 3
Focus group participant demographics
Criterion
No. fulfilling criterion
Large
laboratories
Small
laboratories
Microbiology
laboratories
Public health
laboratories
State Public Health Laboratory 0 0 0 8
Local Public Health Laboratory 0 0 1 2
State Agricultural Laboratory 0 0 0 1
Manufacturing Industry Laboratory 1 0 0 0
Independent/Commercial Laboratory 1 2 0 0
Physician Office Laboratory 2 5 0 0
University/Medical School Laboratory 1 0 4 0
Large Hospital/Clinic Laboratory 13 6 13 0
CLIA Certificate of Compliance 0 4 0 5
CLIA Certificate of Accreditation 18 9 18 6
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Table 4
Proficiency testing benefits beyond meeting regulatory requirements
Topic Benefits Examples
PT use in quality 
management
Competency, 
education, and 
training
• Results can be used to identify staff that may require more training.
• Remaining samples can be used to assess staff competencies.
• Remaining samples can be used for staff education and training.
• Samples can provide an important source of rarely seen organisms.
Quality evaluation 
and improvement
• Scores can indicate areas where improvement may be needed.
• Scores can be used in defense of quality of testing and results with upper 
management.
• Scores can be used to defend the quality of laboratory results when 
occasionally challenged by a clinician.
Assessment of 
methodology/ 
instrumentation
• Remaining samples can be used to test the accuracy of various systems, 
validate new instrumentation, verify accuracy with laboratory-developed 
tests, and troubleshoot analyzers.
• Summary reports can be used to obtain information on PT performance 
to change or recommend a change in methodology or instrument.
- Compare instruments when results are peer grouped
- Identify methodologies/instrumentation used by the majority 
of laboratories
Trending • Results can be used to monitor trends in performance over time.
• Trends can be used to identify a problem before it becomes significant.
PT program satisfaction
Turnaround times • Time from PT sample receipt to submission of test results to PT program 
was adequate to perform and report testing.
Technical advice • Programs provide educational challenges with added information.
• Programs provide additional information on their websites regarding 
ungraded challenges.
• Technical experts were knowledgeable.
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Table 5
Proficiency testing challenges experienced by clinical laboratory professionals
Topic Benefits Examples
PT sample identification/handling PT samples treated the same as patient 
specimens
• PT samples do not physically resemble 
patient specimens, which makes it difficult to 
handle and treat them the same.
• Samples require more instruction on handling 
and safety precautions, reconstitution, testing, 
and reporting results than patient specimens.
• Additional documentation required for PT 
samples may lead to potential for 
transcription errors.
• Entering PT information into an electronic 
laboratory information system (LIS) may 
result in errors in computation and 
conclusions for non-analytical purposes.
PT use in quality management
Total testing process evaluation • PT has limited value in the pre- and post-
analytic phases of testing.
Methodology/instrumentation assessment • Determination as to which analyzer should be 
designated for analysis and for reporting 
when the test is performed on multiple 
analyzers may result in additional tracking 
and paperwork.
Competency, education, and training • Fear of failure is a concern.
• Staff are held accountable for the results by 
management, and consequences of failure can 
be serious for laboratorians.
Trending • PT results at the extreme high and low ends 
of the analytical range may result in data that 
are less useful for methodology and 
instrument monitoring.
• Trending is not useful in microbiology 
because samples are repeated less frequently.
Technical challenges
PT sample unavailability • Developing an alternative PT program when 
samples or analytes are not available 
commercially can be challenging.
• There is sometimes a lag time until the PT 
program provides tests for new instruments 
or methodologies.
Matrix effect • PT sample matrices are unlike patient 
specimens and can lead to testing issues.
Ungraded PT challenges • Corrective action with documentation is 
necessary and involves extended staff time.
Administrative challenges
PT program costs • Expense of PT can be difficult to justify in 
the budget.
• Sometimes it is necessary to purchase 
multiple modules to cover all analytes tested.
Staff time • PT is time-consuming and difficult to 
incorporate into daily workload.
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Topic Benefits Examples
• Extensive time is needed for documentation, 
ordering PT, reporting results, managing 
paperwork volume, and clerical review.
• LIS may handle PT data differently than 
patient data, and extra time is needed to 
process it.
PT program satisfaction
PT sample quality/quantity • Poorly stained slides
• Distorted images in photomicrographs
• Quantity not enough for a repeat test
• Complex reconstitution instructions
• Lack of sample source information with 
microbiology samples
• Susceptibility testing issues due to number of 
passes of an organism
PT reporting unit consistency • PT reported in units that are different from 
those used to report patient specimens
• Need to perform unit conversions
• PT program changes reporting units
PT reporting format • Different reporting format for each PT 
program
• Process different from how patient specimens 
would be reported
Customer service • Automated telephone response system does 
not provide opportunity to talk with a live 
person.
• Difficult to reach a technical expert
Turnaround times • Unable to rerun labile samples
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Table 6
Recommendations for improvement
Topic Examples
PT cost • Provide customized modules.
Sample/PT modules • Provide PT samples that more closely resemble patient specimens.
• Decrease number of negative samples.
• Provide more complex organism samples.
• Resolve CLSI and FDA susceptibility testing breakpoint differences.
PT reporting • Reduce paperwork.
• Provide uniform reporting procedures across modules.
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